Efficacy and safety of Hyper-CVAD regimen for treatment of aggressive T-cell lymphoma
10.3760/cma.j.issn.1009-9921.2018.01.008
- VernacularTitle:Hyper-CVAD方案治疗侵袭性T细胞淋巴瘤的效果和安全性
- Author:
Huacong CAI
1
;
Jing CUI
;
Daobin ZHOU
;
Minghui DUAN
;
Tienan ZHU
;
Jian LI
;
Junling ZHUANG
;
Bing HAN
;
Wei ZHANG
Author Information
1. 100730,中国医学科学院 北京协和医学院 北京协和医院血液内科
- Keywords:
Lymphoma;
T-cell;
aggressive;
Antineoplastic combined chemotherapy protocols;
Efficacy;
Safety
- From:
Journal of Leukemia & Lymphoma
2018;27(1):28-32,36
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of Hyper-CVAD intensive chemotherapy regimen in patients with newly diagnosed aggressive T-cell lymphoma. Methods The efficacy, side effects and survival status were retrospectively analyzed in 34 patients with newly diagnosed aggressive T-cell lymphoma who received Hyper-CVAD regimen as induction therapy in Peking Union Medical College Hospital from September 2009 to December 2010. Results Of 34 patients, 28 cases (82.4 ％) showed treatment response, including 10 cases (29.4 ％) of complete response (CR). Eleven patients underwent stem cell transplantation, including 1 case of human leukocyte antigen-identical siblings allogeneic stem cell transplantation. The median follow-up was 16 months (1-82 months), and the overall survival (OS) rate of 1 or 3-year was 70.2 ％ and 41.1 ％ respectively, and progression-free survival (PFS) rate of 1 or 3-year was 49.3 ％ and 31.6 ％ respectively. The major adverse reaction was myelosuppresion, including 18 cases (52.9％) of myelosuppresion with grade Ⅳ. Three patients died of serious infection. Cox regression multifactor analysis showed CR was the only influencing factor for PFS (HR=6.118, 95％CI 1.327-28.206, P=0.020). Marrow involvement (HR= 0.270, 95 ％CI 0.101-0.722, P= 0.009) and CR (HR= 6.669, 95 ％CI 1.754-25.354, P= 0.005) were independent influencing factors for OS. Conclusions Hyper-CVAD regimen has a high response rate for aggressive T-cell lymphoma, but the lasting effectiveness and the short-term efficacy show unfavorable performances. Meanwhile, myelosuppression is serious and infection incidence is high. Autologous hematopoietic stem-cell transplantation after remission may improve the outcome.
